

AMENDMENTS TO THE CLAIMS

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

1-2. **(Canceled)**

3. **(Currently amended)** A method of classifying a breast tumor comprising steps of:
providing a breast tumor sample;
detecting expression or activity of a gene encoding the polypeptide of SEQ ID NO:3 in the sample; and
classifying the tumor as belonging to a tumor subclass based on the results of the detecting step.

4. **(Canceled)**

5. **(Currently amended)** The method of claim 3, ~~any of claims 1, 2, 3, or 4~~, wherein the detecting step comprises detecting the polypeptide of SEQ ID NO:3 ~~or polypeptides~~.

6. **(Original)** The method of claim 5, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.

7. **(Original)** The method of claim 5, wherein the polypeptide is detected by performing an ELISA assay using an antibody that specifically binds to the polypeptide.

8. **(Original)** The method of claim 5, wherein the polypeptide is detected using an antibody array comprising an antibody that specifically binds to the polypeptide.

9. **(Previously presented)** The method of claim 5, wherein the polypeptide is detected by detecting modification of a substrate by the polypeptide.
10. **(Currently amended)** The method of claim 3, any of claims 1, 2, 3, or 4, wherein, in the step of providing, the sample is isolated from a subject having a tumor, the method further comprising:
 stratifying the subject having the tumor for a clinical trial based on the results of the classifying step.
11. **(Canceled)**
12. **(Currently amended)** The method of claim 3, any of claims 1, 2, 3, or 4, wherein the ~~tumor is a breast tumor and~~ the tumor subclass is a basal tumor subclass.
- 13-14. **(Canceled)**
15. **(Currently amended)** ~~The method of claim 3, further comprising:~~ A method of providing diagnostic, prognostic, or predictive information for a breast tumor comprising steps of:
 providing a breast tumor sample;
 detecting expression or activity of a gene encoding the polypeptide of SEQ ID NO:3 in the sample;
 classifying the tumor as belonging to a tumor subclass based on the results of the detecting step; and
 providing diagnostic, prognostic, or predictive information based on the classifying step.
16. **(Canceled)**

17. (Currently amended) The method of claim 15 wherein the detecting step comprises detecting the polypeptide of SEQ ID NO:3 ~~claim 5, further comprising:~~
~~providing diagnostic, prognostic, or predictive information based on the classifying step.~~

18. **(Original)** The method of claim 17, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.

19. **(Original)** The method of claim 17, wherein the polypeptide is detected by performing an ELISA assay using an antibody that specifically binds to the polypeptide.

20. **(Original)** The method of claim 17, wherein the polypeptide is detected using an antibody array comprising an antibody that specifically binds to the polypeptide.

21. **(Previously presented)** The method of claim 17, wherein the polypeptide is detected by detecting modification of a substrate by the polypeptide.

22. **(Currently amended)** The method of claim 15, any of claims 13, 14, 15, or 16, wherein ~~the tumor is a breast tumor and~~ the tumor subclass is a basal tumor subclass.

23-24. **(Canceled)**

25. (Currently amended) ~~The method of claim 3, further comprising:~~ A method of selecting a treatment for a breast tumor comprising steps of:
providing a breast tumor sample;
detecting expression or activity of a gene encoding the polypeptide of SEQ ID NO:3 in

the sample;

classifying the tumor as belonging to a tumor subclass based on the results of the
detecting step; and
selecting a treatment based on the classifying step.

26. **(Canceled)**

27. **(Currently amended)** The method of claim 25 wherein the detecting step comprises
detecting the polypeptide of SEQ ID NO:3 ~~claim 5, further comprising:~~
~~selecting a treatment based on the classifying step.~~

28. **(Original)** The method of claim 27, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.

29. **(Original)** The method of claim 27, wherein the polypeptide is detected by performing an ELISA assay using an antibody that specifically binds to the polypeptide.

30. **(Original)** The method of claim 27, wherein the polypeptide is detected using an antibody array comprising an antibody that specifically binds to the polypeptide.

31. **(Previously presented)** The method of claim 27, wherein the polypeptide is detected by detecting modification of a substrate by the polypeptide.

32. **(Currently amended)** The method of claim 25, any of claims 23, 24, 25, or 26, wherein ~~the tumor is a breast tumor and~~ the tumor subclass is a basal tumor subclass.

33-34. **(Canceled)**

35. **(Currently amended)** A method of providing diagnostic, prognostic, or predictive information about a subject having a breast tumor comprising steps of:

- providing a sample isolated from a subject having a breast tumor;
- detecting expression or activity of a gene encoding the polypeptide of SEQ ID NO:3 in the sample; and
- providing diagnostic, prognostic, or predictive information about the subject based on the results of the detecting step.

36. **(Canceled)**

37. **(Currently amended)** The method of claim 35, ~~any of claims 33, 34, 35, or 36~~, wherein the detecting step comprises detecting the polypeptide of SEQ ID NO:3 ~~or polypeptides~~.

38. **(Original)** The method of claim 37, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.

39. **(Original)** The method of claim 37, wherein the polypeptide is detected by performing an ELISA assay using an antibody that specifically binds to the polypeptide.

40. **(Original)** The method of claim 37, wherein the polypeptide is detected using an antibody array comprising an antibody that specifically binds to the polypeptide.

41. **(Previously presented)** The method of claim 37, wherein the polypeptide is detected by detecting modification of a substrate by the polypeptide.

42. **(Currently amended)** The method of claim 35, ~~any of claims 33, 34, 35, or 36~~, wherein the sample is selected from the group consisting of:
- a blood sample, a urine sample, a serum sample, an ascites sample, a saliva sample, a cell, and a portion of tissue.
43. **(Currently amended)** The method of claim 35, ~~any of claims 33, 34, 35, or 36~~, wherein the sample is a tumor sample.
- 44-46. **(Canceled)**
47. **(Currently amended)** A method of stratifying a subject having a breast tumor for a clinical trial comprising steps of:
- providing a sample isolated from a subject having a breast tumor;
 - detecting expression or activity of a gene encoding the polypeptide of SEQ ID NO:3 in the sample; and
 - stratifying the subject for a clinical trial based on the results of the detecting step.
48. **(Canceled)**
49. **(Currently amended)** The method of claim 47, ~~any of claims 45, 46, 47, or 48~~, wherein the detecting step comprises detecting the polypeptide or polypeptides.
50. **(Original)** The method of claim 49, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.

51. **(Original)** The method of claim 49, wherein the polypeptide is detected by performing an ELISA assay using an antibody that specifically binds to the polypeptide.
52. **(Original)** The method of claim 49, wherein the polypeptide is detected using an antibody array comprising an antibody that specifically binds to the polypeptide.
53. **(Previously presented)** The method of claim 49, wherein the polypeptide is detected by detecting modification of a substrate by the polypeptide.
54. **(Currently amended)** The method of claim 47, ~~any of claims 45, 46, 47, or 48~~, wherein the sample is selected from the group consisting of:
a blood sample, a urine sample, a serum sample, an ascites sample, a saliva sample, a cell, and a portion of tissue.
55. **(Currently amended)** The method of claim 47, ~~any of claims 45, 46, 47, or 48~~, wherein the sample is a tumor sample.
- 56-58. **(Canceled)**
59. **(Currently amended)** A method of selecting a treatment for a subject having a breast tumor comprising steps of:
providing a sample isolated from a subject having a breast tumor;
detecting expression or activity of a gene encoding the polypeptide of SEQ ID NO:3 in the sample; and
selecting a treatment based on the results of the detecting step.
60. **(Canceled)**

61. **(Currently amended)** The method of claim 59, ~~any of claims 57, 58, 59, or 60~~, wherein the detecting step comprises detecting the polypeptide of SEQ ID NO:3 ~~or polypeptides~~.
62. **(Original)** The method of claim 61, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.
63. **(Original)** The method of claim 61, wherein the polypeptide is detected by performing an ELISA assay using an antibody that specifically binds to the polypeptide.
64. **(Original)** The method of claim 61, wherein the polypeptide is detected using an antibody array comprising an antibody that specifically binds to the polypeptide.
65. **(Previously presented)** The method of claim 61, wherein the polypeptide is detected by detecting modification of a substrate by the polypeptide.
66. **(Currently amended)** The method of claim 59, ~~any of claims 57, 58, 59, or 60~~, wherein the sample is selected from the group consisting of:
a blood sample, a urine sample, a serum sample, an ascites sample, a saliva sample, a cell, and a portion of tissue.
67. **(Currently amended)** The method of claim 59, ~~any of claims 57, 58, 59, or 60~~, wherein the sample is a tumor sample.
- 68-122. **(Canceled)**